Gilead Science (GILD) Followers Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers

GILD 125.67

+0.4%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Wildbiftek	5/15/2020 10:57:56 AM
	of 961

Inhaled version tipped bloomberg.com “It is not a cure,” O’Day says. “It is a first step, but it is an important first step.” Many additional drugs and vaccines will probably be needed to stop the pandemic, he says. Gilead itself is working on an easier-to-administer inhaled form of remdesivir that might be useful for less severe cases. I'm not sure remdesivir itself will impact GILD's bottomline substantially, but they are generating a lot of good will by preempting this major crisis and working with public entities during it. There will likely be a pivot to investing in biotechs, particularly those with a historic specialty in virology in the future and GILD is a well capitalized leader on this front.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next